SecProbe.io

March 17, 2020
Joseph A. Wiley
Chief Executive Officer
Amryt Pharma plc
Dept 920a 196 High Road, Wood Green
London, United Kingdom N22 8HH
Re:Amryt Pharma plc
Draft Registration Statement on Form F-1
Submitted February 19, 2020
CIK No. 0001783010
Dear Dr. Wiley:
            We have reviewed your draft registration statement and have the following comments.  In
some of our comments, we may ask you to provide us with information so we may better
understand your disclosure.
            Please respond to this letter by providing the requested information and either submitting
an amended draft registration statement or publicly filing your registration statement on
EDGAR.  If you do not believe our comments apply to your facts and circumstances or do not
believe an amendment is appropriate, please tell us why in your response.
            After reviewing the information you provide in response to these comments and your
amended draft registration statement or filed registration statement, we may have additional
comments.
Draft Registration Statement on Form F-1
Cover page
1.We note your disclosure on the prospectus cover page that the last reported sale price of
your ordinary shares on the London AIM market was £ ___ per ordinary share, equivalent
to $ ___ per ADS. You may use the most recent home market trading price, converted to
U.S. dollars at the most recent exchange rate, assuming the U.S. IPO price will be
substantially similar to the home market trading price. If you expect that the U.S. IPO
price will not be substantially similar as the home market trading price, please disclose on
the prospectus cover page a bona fide price range of the offered securities. If you intend to
price the securities based on the London AIM market price, you may disclose a percentage
range based on that price (for example, 10% of the home market price) within which you

 FirstName LastNameJoseph A. Wiley
 Comapany NameAmryt Pharma plc
 March 17, 2020 Page 2
 FirstName LastNameJoseph A. Wiley
Amryt Pharma plc
March 17, 2020
Page 2
intend to price the securities. Please refer to the instructions to Item 501(b)(3) of
Regulation S-K which require bona fide pricing information for offerings by companies
not subject to the reporting requirements of Section 13(a) or 15(d) of the Exchange Act.
Prospectus Summary
Overview, page 3
2.We note your disclosure in footnote four to your program chart that AP101 was approved
in 2016 by the European Medicines Agency (EMA) for the treatment of partial thickness
wounds in adults, but has not been commercially launched. We note also your discussion
in the Business section beginning on page 84 of three Phase 3 clinical trials of AP101 for
the treatment of other partial thickness wounds and statement that you do not intend to
pursue this indication but focus your development of AP101 on the treatment
of Epidermolysis Bullosa (EB). Please tell us whether you have been permitted to rely on,
or anticipate being permitted to rely on, data from such clinical trials for the treatment of
partial thickness wounds for purposes of securing marketing approval for the treatment of
EB and if that is not the case, please tell us why you believe such disclosure is
appropriate. Please address as part of your response your presentation of pooled data.
Implications of Being an Emerging Growth Company, page 5
3.Please supplementally provide us with copies of all written communications, as defined
in Rule 405 under the Securities Act, that you, or anyone authorized to do so on your
behalf, present to potential investors in reliance on Section 5(d) of the Securities Act,
whether or not they retain copies of the communications.
Risks Associated with our Business, page 5
4.Please add a bullet point that includes your amount of outstanding debt as of December
31, 2019 and highlights the risk of your debt obligations.
Risk Factors
Risks Related to Our Business, Financial Condition and Capital Resources
Restrictive covenants in certain of the agreements and instruments governing our indebtedness...,
page 15
5.Please expand your risk factor to disclose provisions in your debt agreements that provide
for cross-default with other of your debt agreements, as referenced on pages 135 to 136.

Use of Proceeds, page 57
6.Please revise the discussion to disclose the estimated net amount of the proceeds
broken down into each principal intended use. If the anticipated proceeds will not be
sufficient to fund all the proposed purposes, please disclose the order of priority of such
purposes. To the extent material amounts of other funds are necessary to accomplish the

 FirstName LastNameJoseph A. Wiley
 Comapany NameAmryt Pharma plc
 March 17, 2020 Page 3
 FirstName LastNameJoseph A. Wiley
Amryt Pharma plc
March 17, 2020
Page 3
specified purposes, state the amounts and sources of such other funds needed for each
specified purpose. Refer to Item 3.C.1 of Form 20-F.
Management's Discussion and Analysis and Results of Operations
Research and Development Expenses, page 69
7.Please revise your disclosure to quantify the research and development expenses by
product candidate. To the extent that you do not track expenses by product candidate,
please disclose as such and disclose the costs incurred by the types of costs classified
as research and development for each period presented.
Intellectual Property, page 90
8.Please revise this section to clearly disclose the patents that relate to each of your
commercialized products and development stage products, including the type of patent
protection, whether the patent is issued or pending, the expiry date and relevant
jurisdiction. In this regard, as examples only, we note the following:

• disclosure indicating your lomitapide patent portfolio includes patents that provide
protection into "2027 in the United States and into 2025 in the European Union with
supplementary protection granted to extend patent protection in major EU countries
into 2028" and that granted patents "expire between 2019 and 2030 and pending
patent applications (if granted) would expire at the latest in 2039, or later."
•reference to patents that provide orphan exclusivity for metreleptin for a specified
period; and
•reference to global intellectual property coverage.

Please also revise your discussion of orphan drug exclusivity to clearly distinguish
among granted designations, designations you plan to seek and designations that have
expired.

University College Dublin In-License Agreement, page 91
9.Please revise your disclosure of the termination provisions under the agreement to provide
the anticipated expiry of patents licensed under the agreement, the period of orphan drug
exclusivity and the circumstances under which University College Dublin may terminate
the agreement. Please revise to provide similar disclosure throughout this section where
you reference patent expiry and/or data or market exclusivity with respect to termination
rights. Please also revise to clarify whether the "Completion Date" for purposes of
the Japan Lomitapide License Agreement has occurred.
University of Pennsylvania Lomitapide License Agreement, page 92
10.We note your discosure that if the indication is not homozygous familial
hypercholesterolemia (HoFH) or severe refractory hypercholesterolemia, then additional

 FirstName LastNameJoseph A. Wiley
 Comapany NameAmryt Pharma plc
 March 17, 2020 Page 4
 FirstName LastName
Joseph A. Wiley
Amryt Pharma plc
March 17, 2020
Page 4
payments are required to be made upon the occurence certain milestone events. If
applicable to your development of lomitapide for the treatment of familial
chylomicronemia syndrome (FCS), please revise your disclosure provide your potential
payment obligations.
Amgen License Agreement, page 93
11.Please revise your disclosure of the royalty term under the agreement to provide the
anticipated patent expiry and referenced data exclusivity period. Additionally, please
expand your disclosure of the terms of the National Institutes of Health ( NIH ) License
Agreement to include the circumstances under which NIH may terminate the agreement.
            You may contact Gary Newberry at 202-551-3761 or Kevin Kuhar at 202-551-3662 if
you have questions regarding comments on the financial statements and related matters.  Please
contact Christine Westbrook at 202-551-5019 or Suzanne Hayes at 202-551-3675 with any other
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Boris Dolgonos, Esq.